Company intelligence / Profile preview
ArriVent BioPharma
Newtown Square, Pennsylvania, United Statesarrivent.com ↗
- Ownership
- Public · AVBP
- Employees
- ~52
- Development stage
- Other
01
Overview
ArriVent’s lead candidate firmonertinib has shown robust anti-tumor activity and CNS penetration in NSCLC patients with specific EGFR mutations. The global Phase III trial for first-line NSCLC with EGFR exon 20 insertions has completed enrollment. Interim data also show promising results for patients with PACC mutations. The company’s ADC pipeline is expanding through licensing deals and collaborations, including ARR-217/MRG007 targeting GI cancers now entering clinical development[5][7][9].
- Therapeutic areas
- Oncology
- Modalities
- Small molecules (tyrosine kinase inhibitors)Antibody-drug conjugates (ADCs)
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
Shanghai Allist Pharmaceuticals Co., Ltd. – licensing of firmonertinib/furmonertinib[4]Lepu Biopharma Co., Ltd. – exclusive license for MRG007/ARR‑217 ADC program targeting GI cancers outside Greater China[1][7]Aarvik Therapeutics Inc. – research collaboration using modular antibody platform technology to develop novel oncology drugs[10]Beijing InnoCare Pharma Tech Co., Ltd.[4]Jiangsu Alphamab Biopharmaceuticals Co., Ltd.[4]
04
Financials
- Market cap
- $603M
- Total revenue
- $0
- Enterprise value
- $230.3M
Beyond the preview
Go deeper on ArriVent BioPharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ArriVent BioPharma.